Authors' Reply to Gandjour: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?".
作者信息
Büssgen Melanie, Stargardt Tom
机构信息
Hamburg Center for Health Economics, University of Hamburg, Esplanade 36, 20354, Hamburg, Germany.
出版信息
Appl Health Econ Health Policy. 2024 Jan;22(1):127-128. doi: 10.1007/s40258-023-00851-3. Epub 2023 Dec 2.
Abstract
摘要
相似文献
1
Authors' Reply to Gandjour: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?".
Appl Health Econ Health Policy. 2024 Jan;22(1):127-128. doi: 10.1007/s40258-023-00851-3. Epub 2023 Dec 2.
2
Comment on: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?".
Appl Health Econ Health Policy. 2024 Jan;22(1):125-126. doi: 10.1007/s40258-023-00852-2. Epub 2023 Dec 2.
3
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
Appl Health Econ Health Policy. 2023 Sep;21(5):751-759. doi: 10.1007/s40258-023-00815-7. Epub 2023 May 30.
4
Authors' reply to Gandjour: "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany".
Eur J Health Econ. 2018 Apr;19(3):473-481. doi: 10.1007/s10198-018-0956-4. Epub 2018 Feb 21.
5
Does health technology assessment compromise access to pharmaceuticals?
Eur J Health Econ. 2023 Apr;24(3):437-451. doi: 10.1007/s10198-022-01484-4. Epub 2022 Jun 16.
6
Does health technology assessment compromise access to pharmaceuticals?
Eur J Health Econ. 2023 Sep;24(7):1245-1248. doi: 10.1007/s10198-023-01611-9. Epub 2023 Jun 19.
7
Authors' Reply to Gandjour "The Cost Effectiveness of High-Dose Versus Conventional Haemodialysis: A Systematic Review".
Appl Health Econ Health Policy. 2016 Dec;14(6):731-732. doi: 10.1007/s40258-016-0284-8.
8
Authors' Reply to Gandjour: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation".
Pharmacoeconomics. 2017 May;35(5):605-606. doi: 10.1007/s40273-017-0498-0.
9
Authors' reply to Gandjour: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".
Pharmacoeconomics. 2014 Dec;32(12):1247. doi: 10.1007/s40273-014-0232-0.
10
Authors' Reply to Gandjour: "The Role of Chronic Disease, Obesity, and Improved Treatment and Detection in Accounting for the Rise in Healthcare Spending Between 1987 and 2011".
Appl Health Econ Health Policy. 2016 Apr;14(2):243. doi: 10.1007/s40258-016-0233-6.
引用本文的文献
1
Cost-utility analysis of Lu-PSMA-617 radioligand therapy in second-line and third-line treatment for metastatic castration-resistant prostate cancer (mCRPC) in Germany.
Eur J Nucl Med Mol Imaging. 2025 May 8. doi: 10.1007/s00259-025-07317-9.
本文引用的文献
1
Comment on: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?".
Appl Health Econ Health Policy. 2024 Jan;22(1):125-126. doi: 10.1007/s40258-023-00852-2. Epub 2023 Dec 2.
2
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
Appl Health Econ Health Policy. 2023 Sep;21(5):751-759. doi: 10.1007/s40258-023-00815-7. Epub 2023 May 30.
3
Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients.
Biomark Insights. 2016 Jul 3;11:95-104. doi: 10.4137/BMI.S38440. eCollection 2016.
4
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
Health Technol Assess. 2015 Feb;19(14):1-503, v-vi. doi: 10.3310/hta19140.
Zotero 插件